Zemanová P - Search Results

1

Fibrinolysis defect in long-term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorders.

Opatrný K Jr, Zemanová P, Mares J, Vít L, Opatrná S, Sefrna F, Hejda V, Tomsů M, Eiselt J, Massry SG. Opatrný K Jr, et al. Among authors: zemanova p. Am J Nephrol. 2002 Sep-Dec;22(5-6):429-36. doi: 10.1159/000065270. Am J Nephrol. 2002. PMID: 12381940

2

Tissue factor, its pathway inhibitor, and metabolic disturbances in long-term peritoneal dialysis.

Zemanová P, Opatrný K Jr, Opatrná S, Vít L, Sefrna F, Racek J. Zemanová P, et al. Kidney Blood Press Res. 2003;26(5-6):368-75. doi: 10.1159/000073944. Kidney Blood Press Res. 2003. PMID: 14610342

3

Fibrinolysis in chronic renal failure, dialysis and renal transplantation.

Opatrný K Jr, Zemanová P, Opatrná S, Vít L. Opatrný K Jr, et al. Among authors: zemanova p. Ann Transplant. 2002;7(1):34-43. Ann Transplant. 2002. PMID: 12221902 Free article. Review.

4

Tissue factor, its inhibitor, and the thrombogenicity of two new synthetic membranes.

Zemanova P, Opatrny K, Vit L, Sefrna F. Zemanova P, et al. Artif Organs. 2005 Aug;29(8):651-7. doi: 10.1111/j.1525-1594.2005.29103.x. Artif Organs. 2005. PMID: 16048482 Clinical Trial.

5

Heart failure treated with low-dose milrinone in a full-term newborn.

Sebková S, Tomek V, Zemanová P, Janota J. Sebková S, et al. Among authors: zemanova p. Prague Med Rep. 2012;113(1):58-65. doi: 10.14712/23362936.2015.38. Prague Med Rep. 2012. PMID: 22373807

6

[Costs of type II diabetes in the conditions of the Czech Republic's medical care system].

Dolezal T, Písaríková Z, Zemanová P, Bartásková D. Dolezal T, et al. Among authors: zemanova p. Vnitr Lek. 2009 Apr;55(4):342-4. Vnitr Lek. 2009. PMID: 19449746 Czech.

7

Does Extraesophageal Reflux Support the Development of Lung Adenocarcinoma? Analysis of Pepsin in Bronchoalveolar Lavage in Non-Smoker Patients.

Zemanova P, Vocka M, Vanickova Z, Liska F, Krizova L, Kalab J, Votruba J. Zemanova P, et al. Cancers (Basel). 2024 Jul 28;16(15):2687. doi: 10.3390/cancers16152687. Cancers (Basel). 2024. PMID: 39123415 Free PMC article.

8

Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors.

Krizova L, Benesova I, Zemanova P, Spacek J, Strizova Z, Humlova Z, Mikulova V, Petruzelka L, Vocka M. Krizova L, et al. Among authors: zemanova p. J Cancer Res Clin Oncol. 2024 Feb 21;150(2):99. doi: 10.1007/s00432-024-05628-2. J Cancer Res Clin Oncol. 2024. PMID: 38383923 Free PMC article.

9

Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer.

Blazek J, Hosek P, Hrabcova K, Bratova M, Kultan J, Hrnciarik M, Cernovska M, Zemanova P, Krejci J, Koubkova L, Stastny M, Svaton M. Blazek J, et al. Among authors: zemanova p. In Vivo. 2023 Sep-Oct;37(5):2229-2236. doi: 10.21873/invivo.13324. In Vivo. 2023. PMID: 37652490 Free PMC article.

10

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.

Krejci D, Opalka P, Krejci J, Zemanova M, Zemanova P, Kultan J, Fischer O, Skrickova J, Bratova M, Cernovska M, Hrnciarik M, Coupkova H, Hurdalkova K, Barinova M, Koubkova L, Dolezal D, Safanda M, Pesek M, Svaton M. Krejci D, et al. Among authors: zemanova p. Anticancer Res. 2021 May;41(5):2597-2603. doi: 10.21873/anticanres.15039. Anticancer Res. 2021. PMID: 33952489

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters